120 related articles for article (PubMed ID: 17725389)
1. Generation and characterization of monoclonal antibodies against tuberous sclerosis complex 2.
Malanchuk O; Palchevskyy S; Ovcharenko G; Gwalter J; Pozur V; Gout I; Filonenko V
Hybridoma (Larchmt); 2007 Aug; 26(4):259-66. PubMed ID: 17725389
[TBL] [Abstract][Full Text] [Related]
2. Hamartin and tuberin: working together for tumour suppression.
Jozwiak J
Int J Cancer; 2006 Jan; 118(1):1-5. PubMed ID: 16206276
[TBL] [Abstract][Full Text] [Related]
3. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas.
Plank TL; Logginidou H; Klein-Szanto A; Henske EP
Mod Pathol; 1999 May; 12(5):539-45. PubMed ID: 10349994
[TBL] [Abstract][Full Text] [Related]
4. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of monoclonal antibodies to mTOR kinase.
Nemazanyy I; Breus O; Gout I; Filonenko V; Panasyuk G
Hybridoma (Larchmt); 2008 Oct; 27(5):395-9. PubMed ID: 18803507
[TBL] [Abstract][Full Text] [Related]
6. Hamartin and tuberin modulate gene transcription via beta-catenin.
Jozwiak J; Wlodarski P
J Neurooncol; 2006 Sep; 79(3):229-34. PubMed ID: 16552619
[TBL] [Abstract][Full Text] [Related]
7. Antisense suppression of TSC1 gene product, hamartin, enhances neurite outgrowth in NGF-treated PC12h cells.
Floricel F; Higaki K; Maki H; Nanba E; Ninomiya H; Ohno K
Brain Dev; 2007 Sep; 29(8):502-9. PubMed ID: 17376623
[TBL] [Abstract][Full Text] [Related]
8. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Makovski V; Haklai R; Kloog Y
Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
[TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
10. Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway.
Jozwiak J; Jozwiak S; Grzela T; Lazarczyk M
Neuromolecular Med; 2005; 7(4):287-96. PubMed ID: 16391386
[TBL] [Abstract][Full Text] [Related]
11. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of monoclonal antibodies to protein kinase 2 (CK2) beta subunit.
Panasyuk G; Nemazanyy I; Ovcharenko G; Lyzogubov V; Gout I; Filonenko V
Hybridoma (Larchmt); 2005 Aug; 24(4):206-10. PubMed ID: 16120027
[TBL] [Abstract][Full Text] [Related]
14. [Preparation and characterization of a monoclonal antibody against human c-Kit].
Liu HC; Mao CM; Su XY; Ruan Z; Ding QL; Wang XF; Wang HL; Xi XD
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Jul; 25(7):619-22. PubMed ID: 19737481
[TBL] [Abstract][Full Text] [Related]
15. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination.
Benvenuto G; Li S; Brown SJ; Braverman R; Vass WC; Cheadle JP; Halley DJ; Sampson JR; Wienecke R; DeClue JE
Oncogene; 2000 Dec; 19(54):6306-16. PubMed ID: 11175345
[TBL] [Abstract][Full Text] [Related]
16. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development.
Li S; Takeuchi F; Wang JA; Fuller C; Pacheco-Rodriguez G; Moss J; Darling TN
J Exp Med; 2005 Sep; 202(5):617-24. PubMed ID: 16129702
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
18. Tuberin, p27 and mTOR in different cells.
Burgstaller S; Rosner M; Lindengrün C; Hanneder M; Siegel N; Valli A; Fuchs C; Hengstschläger M
Amino Acids; 2009 Feb; 36(2):297-302. PubMed ID: 18386114
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of Tsc1 and Tsc2 single and double radial glial cell mutants.
Mietzsch U; McKenna J; Reith RM; Way SW; Gambello MJ
J Comp Neurol; 2013 Nov; 521(16):3817-31. PubMed ID: 23749404
[TBL] [Abstract][Full Text] [Related]
20. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.
Nellist M; Sancak O; Goedbloed MA; Rohe C; van Netten D; Mayer K; Tucker-Williams A; van den Ouweland AM; Halley DJ
Eur J Hum Genet; 2005 Jan; 13(1):59-68. PubMed ID: 15483652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
